JOP20170137B1 - صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت - Google Patents
صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانتInfo
- Publication number
- JOP20170137B1 JOP20170137B1 JOP/2017/0137A JOP20170137A JOP20170137B1 JO P20170137 B1 JOP20170137 B1 JO P20170137B1 JO P20170137 A JOP20170137 A JO P20170137A JO P20170137 B1 JOP20170137 B1 JO P20170137B1
- Authority
- JO
- Jordan
- Prior art keywords
- fosnetupitant
- physiologically balanced
- injectable formulations
- balanced injectable
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بجرعات وصيغ قابلة للحقن من فوسنيتوبيتانت وأملاح مقبولة صيدلانيًا منها والتي تكون فعالة، مستقرة كيميائيًا ومتوازنة فسيولوجيًا للسلامة والفاعلية.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345942P | 2016-06-06 | 2016-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20170137B1 true JOP20170137B1 (ar) | 2021-08-17 |
Family
ID=59055193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2017/0137A JOP20170137B1 (ar) | 2016-06-06 | 2017-06-06 | صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US10624911B2 (ar) |
| EP (2) | EP3435980B1 (ar) |
| JP (2) | JP6936817B2 (ar) |
| KR (1) | KR102459416B1 (ar) |
| CN (1) | CN109310627B (ar) |
| AR (1) | AR108676A1 (ar) |
| AU (1) | AU2017276588B2 (ar) |
| BR (1) | BR112018074655B1 (ar) |
| CA (1) | CA3025837C (ar) |
| CL (1) | CL2018003338A1 (ar) |
| CO (1) | CO2018011686A2 (ar) |
| CY (1) | CY1122755T1 (ar) |
| DK (1) | DK3435980T3 (ar) |
| EA (1) | EA036605B1 (ar) |
| EC (1) | ECSP19000169A (ar) |
| ES (1) | ES2771226T3 (ar) |
| GE (1) | GEP20207189B (ar) |
| HR (1) | HRP20200196T1 (ar) |
| IL (1) | IL263126B (ar) |
| JO (1) | JOP20170137B1 (ar) |
| LT (1) | LT3435980T (ar) |
| MA (1) | MA44513B1 (ar) |
| MD (1) | MD3435980T2 (ar) |
| MX (1) | MX376118B (ar) |
| MY (1) | MY194081A (ar) |
| PE (1) | PE20190347A1 (ar) |
| PH (1) | PH12018502524B1 (ar) |
| PL (1) | PL3435980T3 (ar) |
| PT (1) | PT3435980T (ar) |
| RS (1) | RS59852B1 (ar) |
| SG (1) | SG11201809708PA (ar) |
| SI (1) | SI3435980T1 (ar) |
| TW (1) | TWI725191B (ar) |
| UA (1) | UA122285C2 (ar) |
| UY (1) | UY37273A (ar) |
| WO (1) | WO2017211663A1 (ar) |
| ZA (1) | ZA201807932B (ar) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
| WO2023182388A1 (ja) * | 2022-03-23 | 2023-09-28 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
| WO2025036703A1 (en) * | 2023-08-13 | 2025-02-20 | Helsinn Healthcare Sa | Fosnetupitant for administration via intravenous bolus |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
| WO2026002808A1 (en) | 2024-06-24 | 2026-01-02 | Helsinn Healthcare Sa | Prevention of nausea and vomiting from antibody-drug conjugates and other long-acting emetogenics |
| CN119185243A (zh) * | 2024-11-28 | 2024-12-27 | 山东齐都药业有限公司 | 福奈妥匹坦帕洛诺司琼口服掩味颗粒剂及其制备方法与应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL166267B1 (pl) * | 1989-11-28 | 1995-04-28 | Syntex Inc | Sposób wytwarzania nowych zwiazków trójpierscieniowych PL PL PL PL |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| IL112134A (en) | 1993-12-29 | 1999-12-22 | Merck Sharp & Dohme | Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them |
| IL112778A0 (en) | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
| JO2735B1 (ar) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | التشكيلات الصيدلانية السائلة للبالونوسترون |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| CN105412110B (zh) * | 2011-10-18 | 2018-05-25 | 赫尔森保健股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| PL2866797T3 (pl) * | 2012-07-06 | 2020-11-02 | Pharmathen S.A. | Stabilna, nadająca się do wstrzykiwania kompozycja farmaceutyczna antagonisty receptora neurokininy-1 i sposób jej wytwarzania |
-
2017
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/en active Active
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/en not_active Withdrawn
- 2017-06-01 MX MX2018015036A patent/MX376118B/es active IP Right Grant
- 2017-06-01 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 PH PH1/2018/502524A patent/PH12018502524B1/en unknown
- 2017-06-01 GE GEAP202014974A patent/GEP20207189B/en unknown
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en not_active Ceased
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active Active
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US12208109B2/en active Active
-
2024
- 2024-12-23 US US18/999,533 patent/US20250235473A1/en active Pending
-
2025
- 2025-10-01 US US19/347,686 patent/US20260027138A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124007T1 (el) | Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης | |
| CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
| JOP20170137B1 (ar) | صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت | |
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| EA201792591A1 (ru) | Фармацевтические препараты | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| IN2014CH00840A (ar) | ||
| BR112018006206A2 (pt) | composição, uso de uma combinação, forma de dosagem fixa farmacêutica, combinação de dosagem fixa, embalagem, e, uso de uma combinação de dose fixa | |
| MX376741B (es) | Composición farmaceútica de sulfonamida | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| MX2019010993A (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| EA201991265A1 (ru) | Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат | |
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| IN2014MU00859A (ar) | ||
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
| CY1124539T1 (el) | Φαρμακευτικες συνθεσεις του ανταγωνιστη 5-ητ6 | |
| MX2016013428A (es) | Composiciones farmaceuticas que comprenden agentes antibacterianos. | |
| IN2013MU03422A (ar) | ||
| IN2013MU03309A (ar) | ||
| PH12016502527A1 (en) | Stabilized desmopressin | |
| CY1123966T1 (el) | Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας |